2. Search Result
Search Result
Results for "

Antileukemic activity

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

7

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117996
    KPT-251

    		CRM1 Apoptosis Cancer
    KPT-251 is an orally active chromosome region maintenance 1 protein (CRM1) inhibitor. KPT-251 induces cancer cell apoptosis and shows antileukemic activity .
    KPT-251
  • HY-N3171A
    (+)-Nortrachelogenin

    Wikstromol

    		 Apoptosis PI3K Cancer
    (+)-Nortrachelogenin (Wikstromol), a pharmacologically ligand from from wikstroemia indica, possesses antileukemic activity .
    (+)-Nortrachelogenin
  • HY-135190
    (-)-Cedrene
    2 Publications Verification

    α-cedrene

    		 Bacterial Infection Metabolic Disease Cancer
    (-)-Cedrene (α-cedrene) is a sesquiterpene constituent of cedarwood oils, with anti-leukemic, antimicrobial and anti-obesity activities .
    (-)-Cedrene
  • HY-111008
    Trimidox

    VF-233

    		 DNA/RNA Synthesis Cancer
    Trimidox (VF-233) is a ribonucleotide reductase inhibitor with antileukemic activities. Trimidox inhibits the growth of human promyelocytic leukemia HL-60 cells with an IC50 of 35 μM .
    Trimidox
  • HY-111008A
    Trimidox hydrochloride

    VF-233 hydrochloride

    		 DNA/RNA Synthesis Cancer
    Trimidox hydrochloride (VF-233) is a ribonucleotide reductase inhibitor with antileukemic activities. Trimidox hydrochloride inhibits the growth of human promyelocytic leukemia HL-60 cells with an IC50 of 35 μM .
    Trimidox hydrochloride
  • HY-117237
    Hisphen

    MD 1

    		 Others Cancer
    Hisphen is a chemical mutagen that can affect the grain protein content . Hisphen also has antileukemic activities .
    Hisphen
  • HY-135771
    Avarone

    (+)-Avarone

    		 Others Cancer
    Avarone ((+)-Avarone) is a sesquiterpenoidal quinone that can be isolated from Dysidea avara. Avarone shows cytotoxicity. Avarone shows antileukemic activity .
    Avarone
  • HY-109117
    Iadademstat

    ORY-1001

    		 Histone Demethylase Cancer
    Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .
    Iadademstat
  • HY-N7549
    Dehydrobruceantin

    		Others Cancer
    Dehydrobruceantin has potential antileukemic activity .
    Dehydrobruceantin
  • HY-133900
    Deoxyharringtonine

    		Others Cancer
    Deoxyharringtonine is an alkaloid isolated from Cephalotaxus genus with significant anti-leukemic activity .
    Deoxyharringtonine
  • HY-N0838
    Cephalotaxine

    (-)-Cephalotaxine; ZINC19795976

    		 Flavivirus Infection Cancer
    Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity .
    Cephalotaxine
  • HY-U00095
    Hepsulfam

    NCI 329680; ZINC01574758

    		 Others Cancer
    Hepsulfam (NCI 329680; ZINC01574758) is a anticancer agent that shows excellent antileukemic activity with an median IC50 of 0.91 μg/mL in a panel of different tumors.
    Hepsulfam
  • HY-N8402
    Germacrone 4,5-epoxide

    		Others Cancer
    Germacrone 4,5-epoxide is a sesquiterpene that can be isolated from Curcuma cf. viridiflora. Germacrone 4,5-epoxide has excellent anti-leukemic activities .
    Germacrone 4,5-epoxide
  • HY-123523
    Enocitabine

    		Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CMV Infection Cancer
    Enocitabine is a nucleoside analog, and is a potent DNA replication inhibitor, and a DNA chain terminator. Enocitabine inhibits the replication of human cytomegalovirus. Enocitabine has antileukemic and antiviral activities .
    Enocitabine
  • HY-118144
    PD166326

    		BCRP Src Cancer
    PD166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases, with IC50s of 6 nM and 8 nM for Src and Abl, respectively. PD166326 exhibits antileukemic activity .
    PD166326
  • HY-123718
    6-Benzylthioinosine

    		Others Others
    6-Benzylthioinosine is a compound with antileukemic activity that increases cytotoxicity against acute myeloid leukemia cells when combined with metformin, modulating cellular metabolism and signaling pathways through multiple mechanisms.
    6-Benzylthioinosine
  • HY-106689
    Dihydro-5-azacytidine

    DHAC; NSC 264880

    		 Nucleoside Antimetabolite/Analog DNA Methyltransferase Cancer
    Dihydro-5-azacytidine (DHAC), the nucleoside analog, is incorporated into DNA and inhibits DNA methylation. Dihydro-5-azacytidine has an antitumor activity .
    Dihydro-5-azacytidine
  • HY-119827
    Moflomycin

    F 860191

    		 Others Cancer
    Moflomycin (F 860191) is a compound with strong anti-leukemic activity and low mutagenicity. Moflomycin has an antiproliferative effect on the leukemic cell line HL60 in vitro (IC50=2.9 nM) .
    Moflomycin
  • HY-149334
    ZLD115

    		Fat Mass and Obesity-associated Protein (FTO) Metabolic Disease
    ZLD115 (compound 44) is a FB23-derivated inhibitor of Fat Mass and Obesity-associated Protein (FTO). ZLD115 is an antileukemic agent, exhibiting antiproliferative activity against leukemic cell lines .
    ZLD115
  • HY-115754
    S-(N-PhenethylthiocarbaMoyl)-L-cysteine

    PEITC-Cys

    		 DNA/RNA Synthesis Cytochrome P450 Cancer
    S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys), an anticarcinogenic agent, has antileukemic activity. S-(N-PhenethylthiocarbaMoyl)-L-cysteine inhibits DNA synthesis in HL60 cells . S-(N-PhenethylthiocarbaMoyl)-L-cysteine is a P450 inhibitor .
    S-(N-PhenethylthiocarbaMoyl)-L-cysteine
  • HY-119361
    (Rac)-Deox B 7,4

    (Rac)-Deoxysappanone B 7,4' dimethyl ether

    		 Microtubule/Tubulin Cancer
    (Rac)-Deox B 7,4, a homoisoflavanoid compound, inhibits microtubule polymerization via binding near the colchicine site and promote reversible G2 arrest. (Rac)-Deox B 7,4 possesses nanomolar anti-leukemic activity .
    (Rac)-Deox B 7,4
  • HY-112885A
    nor-NOHA acetate

    Nω-Hydroxy-nor-L-arginine acetate

    		 Arginase Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA acetate
  • HY-141430
    AS-85

    		Histone Methyltransferase Cancer
    AS-85 is a potent ASH1L histone methyltransferase inhibitor (IC50=0.6 µM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the Kd value of 0.78 µM .
    AS-85
  • HY-P2970
    Stem bromelain

    		Apoptosis Inflammation/Immunology Cancer
    Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .
    Stem bromelain
  • HY-123954
    BTX-A51

    Casein Kinase inhibitor A51

    		 Casein Kinase CDK Apoptosis Cancer
    BTX-A51 (Casein Kinase inhibitor A51) is a potent and orally active casein kinase 1α (CK1α) inhibitor. BTX-A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
    BTX-A51
  • HY-112885C
    nor-NOHA dihydrochloride
    2 Publications Verification

    Nω-Hydroxy-nor-L-arginine dihydrochloride

    		 Apoptosis Arginase Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA dihydrochloride is a selective and reversible arginase inhibitor. nor-NOHA dihydrochloride induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA dihydrochloride has anti-leukemic activity. nor-NOHA dihydrochloride can used in study endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA dihydrochloride
  • HY-151897
    HDAC-IN-49

    		HDAC Cancer
    HDAC-IN-49 is a potent unselective HDAC (HDAC) inhibitor with IC50s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .
    HDAC-IN-49
  • HY-112885
    nor-NOHA

    Nω-Hydroxy-nor-L-arginine

    		 Apoptosis Arginase Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA
  • HY-15003
    ATH686

    		FLT3 Apoptosis Cancer
    ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects .
    ATH686
  • HY-112885B
    nor-NOHA monoacetate
    2 Publications Verification

    Nω-Hydroxy-nor-L-arginine monoacetate

    		 Arginase Metabolic Disease
    nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA monoacetate
  • HY-141429
    AS-99 free base

    		Histone Methyltransferase Apoptosis Cancer
    AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99 free base
  • HY-141429C
    AS-99

    		Histone Methyltransferase Apoptosis Cancer
    AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99
  • HY-162658
    Leuxinostat

    		HDAC Apoptosis Cancer
    Leuxinostat is an inhibitor for HDAC with IC50 of 30 nM for hHDAC6. Leuxinostat inhibits the proliferation of cells THP1, K562, U937 and MEK1, induces apoptosis in leukemia cells NB4 and MOLT-4. Leuxinostat inhibits the expansion of hematopoietic stem cells and exhibits antileukemic activity in zebrafish models .
    Leuxinostat
  • HY-141429A
    AS-99 TFA

    		Histone Methyltransferase Apoptosis Cancer
    AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99 TFA
  • HY-163803
    CM-444

    		HDAC DNA Methyltransferase Cancer
    CM-444 is inhibitor for HDAC (IC50 is 6 nM-0.6 μM) and DNA methyltransferases (DNMT, IC50 is 1.8-2.3 μM). CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models .
    CM-444
  • HY-112041
    Unesbulin
    3 Publications Verification

    PTC596

    		 BMI1 Apoptosis Cancer
    Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity .
    Unesbulin
  • HY-123955
    Casein Kinase inhibitor A86

    		Casein Kinase CDK Apoptosis Cancer
    Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
    Casein Kinase inhibitor A86
  • HY-143278
    FLT3-IN-13

    		Topoisomerase FLT3 Apoptosis Cancer
    FLT3-IN-13 (compound 20) is a potent and effective antileukemic topoisomerase II and FLT3 dual inhibitor with IC50 values of 2.26 μM and 2.26 μM, respectively. FLT3-IN-13 arrests cell cycle at G2/M phase and induce apoptosis. FLT3-IN-13 has anticytotoxic activity, particularly against leukemia .
    FLT3-IN-13
  • HY-100423
    Eltanexor
    1 Publications Verification

    KPT-8602

    		 CRM1 Cancer
    Eltanexor (KPT-8602) is a second-generation, highly specific and orally active exportin-1 (XPO1) inhibitor with potent anti-leukemic activity. Eltanexor (KPT-8602) inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor (KPT-8602) induces Caspase-dependent apoptosis in a panel of leukemic cell lines .
    Eltanexor
  • HY-157327
    AKE-72

    		Bcr-Abl Cancer
    AKE-72 (compound 5) is a potent inhibitor of Pan-BCR-ABL. AKE-72 inhibits BCR-ABL WT, BCR-ABL T315, BCR-ABL E255K, BCR-ABL F3171, BCR-ABL H396P and BCR-ABL Q252H with IC50s of < 0.5, 9, 8.98, 3.12, < 1.0 and 3.88 nM, respectively. AKE-72 has anti-leukemic activity against K-562 cell line .
    AKE-72
  • HY-112654A
    GCN2iB acetate

    		Others Cancer
    GCN2iB acetate is a GCN2 inhibitor that enhances Gcn2 activity and Atf4 expression. GCN2iB can activate Gcn2 mutants lacking functional regulatory regions or certain kinase domain substitution mutants. GCN2iB increases eIF2 phosphorylation by Gcn2 at low concentrations, thereby enhancing the cellular response to nutritional stress. GCN2iB may have potential benefits for the inhibition of cancer cells expressing low basal levels of aspartate synthetase, enhancing their sensitivity to the anti-leukemic compound L-aspartase .
    GCN2iB acetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: